The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has today announced the election of fifty new Fellows, including six academics from the University of Oxford.
The six new Oxford Fellows are:
Dave Bennett studies the response of the nervous system to injury in order to develop strategies to promote nerve repair and to both prevent and treat neuropathic pain. He uses a multi-disciplinary approach ranging from the molecular understanding of ion channel function to psychophysical and genetic studies in patients. His research programme is improving understanding of the signalling events which lead to neuropathic pain, enhancing means of patient stratification, and identifying new analgesic drug targets which are undergoing clinical trials. Read more
Peter Brown’s work concerns brain activity in people with Parkinson’s disease. Over the last two decades he has established that synchronised oscillations amongst nerve cells in the basal ganglia of the brains of patients with Parkinson’s are linked to symptoms of stiffness and slowness, and has successfully pioneered therapeutic interventions that leverage this phenomenon. Read more
Ervin Fodor focuses on the fundamental molecular mechanisms of influenza virus replication, aiming to understand the molecular determinants of host range and virulence of influenza viruses. By gaining further insights into the molecular details of influenza virus replication he aims to facilitate the development of novel strategies to combat influenza. Read more
Peter Friend works on the application of isolated perfusion of abdominal organs in a number of therapeutic areas. In particular, perfusion of the liver with oxygenated blood at normal body temperature allows recovery from damage and extended preservation for transplantation – technology which has now entered clinical practice. In addition, his clinical research portfolio includes novel immunosuppressive strategies, with both early-stage studies and larger-scale multi-centre trials.
Cornelia van Duijn focuses on large-scale studies of neurodegenerative disorders including Alzheimer’s, Parkinson’s and Creutzfeldt–Jakob diseases and ophthalmological disorders including glaucoma, age-related macular degeneration and myopia. She further studies systemic vascular, endocrine and gastrointestinal pathology that is relevant for brain and ocular function. Her current research portfolio includes cross-omics research integrating (epi)genetic, transcriptomic, proteomic, metabolomic and microbiome data of epidemiological cohorts with state of the art brain imaging and cellular model systems. Read more
Matthew Wood’s research is in the field of RNA-based precision medicines for rare, inherited neurological diseases. A major focus is oligonucleotide therapeutics and development of peptide-based oligonucleotide compounds for modification of mRNA splicing in Duchenne muscular dystrophy and related disorders. In addition, seminal studies of extracellular vesicles have resulted in development of extracellular vesicle-based nanotechnologies for delivery of RNA medicines to the brain and other tissues. Collectively this work aims to realise the potential of genomic medicines to impact currently untreatable neurological disorders.